about
Therapeutic Potential of Tea Tree Oil for ScabiesLook-alike, sound-alike medication errors: a novel case concerning a Slow-Na, Slow-K prescribing errorScabies: an ancient global disease with a need for new therapies.Case report of a medication error: In the eye of the beholderMalnutrition: The Importance of Identification, Documentation, and Coding in the Acute Care Setting.Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.Topical ivermectin 0.5% lotion for treatment of head lice.Pharmacist review prevents evolving metformin-associated lactic acidosis.Paracetamol and analgesic nephropathy: Are you kidneying me?A systematic review of community pharmacist therapeutic knowledge of dietary supplements.Nutrition Screening Practices amongst Australian Residential Aged Care Facilities.Sleep Disturbances and Nightmares in a Patient Treated with Prazosin.Safe to crush? A pilot study into solid dosage form modification in aged care.Seeing red: over-the-counter chloramphenicol.Role of pharmacists in collaborative care of travellers with chronic conditions.Travelling with medications and medical equipment across international borders.Malnutrition Prevalence in Aged Care ResidentsIdentification of Patients At-Risk of QT Interval Prolongation during Medication Reviews: A Missed Opportunity?Quality use of medicines in aged care facilities: A need for new models of careEvaluation of Pharmaceutical Compounding Training in the Australian Undergraduate Pharmacy CurriculaThe effect of a residential care pharmacist on medication administration practices in aged care: A controlled trial
P50
Q26770884-A8BA388F-10A5-465B-A483-39FEE1DD1F00Q35110958-5D97D11F-2372-471F-A1E4-491C74E2C0C1Q35677899-B1B1B6D2-63B5-4980-8EAD-6A00A6ADD488Q37116862-C763F708-8F35-49E8-8B4B-5DD3B2BD0734Q37330034-7DB60048-64BD-438F-A878-DF3CF89F6328Q37861982-998D54B3-D5FA-44AD-B70A-BDF4DEC086E2Q38164690-48738EBB-50B4-4280-88FC-F3DD7F92D2C3Q38225699-81A19CC3-43E9-45EF-9EEF-31C6B78A116DQ38303567-C1CA8A7A-958F-4FDD-8D8C-10D0B41A3161Q38375128-596A620D-6C6A-4CD8-AD44-103ACD7649CAQ39031271-0D4D939A-7D69-4DAB-ABCD-DA9E99288A39Q39083649-B77C7930-7C15-4AA4-BC4B-633506BB410CQ44383516-09436284-C622-4540-88AD-4E34C2625831Q45227464-3E74CD4E-5B22-4B03-8D26-3782F9C6D368Q47864805-9B0DF320-F278-49AD-A395-4CB28D766CACQ53085472-BE9CA68B-18BC-42EB-9518-662107DC815AQ60511928-1CA84904-147E-4368-8631-BC8F1A150242Q60961481-C44CAD38-08CA-4199-90E8-8B8FD945DAD2Q88748976-D1AC6573-8A60-480F-817B-6B5B3D3E2DBCQ89944133-189B404C-5EC4-4CF0-B9E8-E372532ED59FQ91822052-37587C31-A3B6-4FED-BA8E-432CA841E1CA
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mark Naunton
@ast
Mark Naunton
@en
Mark Naunton
@es
Mark Naunton
@nl
type
label
Mark Naunton
@ast
Mark Naunton
@en
Mark Naunton
@es
Mark Naunton
@nl
prefLabel
Mark Naunton
@ast
Mark Naunton
@en
Mark Naunton
@es
Mark Naunton
@nl
P106
P21
P31
P496
0000-0002-6422-7170